291 related articles for article (PubMed ID: 22322301)
1. Laminin-111 protein therapy reduces muscle pathology and improves viability of a mouse model of merosin-deficient congenital muscular dystrophy.
Rooney JE; Knapp JR; Hodges BL; Wuebbles RD; Burkin DJ
Am J Pathol; 2012 Apr; 180(4):1593-602. PubMed ID: 22322301
[TBL] [Abstract][Full Text] [Related]
2. Transgenic overexpression of the α7 integrin reduces muscle pathology and improves viability in the dy(W) mouse model of merosin-deficient congenital muscular dystrophy type 1A.
Doe JA; Wuebbles RD; Allred ET; Rooney JE; Elorza M; Burkin DJ
J Cell Sci; 2011 Jul; 124(Pt 13):2287-97. PubMed ID: 21652631
[TBL] [Abstract][Full Text] [Related]
3. Autophagy is increased in laminin α2 chain-deficient muscle and its inhibition improves muscle morphology in a mouse model of MDC1A.
Carmignac V; Svensson M; Körner Z; Elowsson L; Matsumura C; Gawlik KI; Allamand V; Durbeej M
Hum Mol Genet; 2011 Dec; 20(24):4891-902. PubMed ID: 21920942
[TBL] [Abstract][Full Text] [Related]
4. Laminin-111 improves muscle repair in a mouse model of merosin-deficient congenital muscular dystrophy.
Van Ry PM; Minogue P; Hodges BL; Burkin DJ
Hum Mol Genet; 2014 Jan; 23(2):383-96. PubMed ID: 24009313
[TBL] [Abstract][Full Text] [Related]
5. Ku70 regulates Bax-mediated pathogenesis in laminin-alpha2-deficient human muscle cells and mouse models of congenital muscular dystrophy.
Vishnudas VK; Miller JB
Hum Mol Genet; 2009 Dec; 18(23):4467-77. PubMed ID: 19692349
[TBL] [Abstract][Full Text] [Related]
6. Exon Skipping Using Antisense Oligonucleotides for Laminin-Alpha2-Deficient Muscular Dystrophy.
Hara Y; Mizobe Y; Miyatake S; Takizawa H; Nagata T; Yokota T; Takeda S; Aoki Y
Methods Mol Biol; 2018; 1828():553-564. PubMed ID: 30171567
[TBL] [Abstract][Full Text] [Related]
7. Distribution of ten laminin chains in dystrophic and regenerating muscles.
Patton BL; Connoll AM; Martin PT; Cunningham JM; Mehta S; Pestronk A; Miner JH; Sanes JR
Neuromuscul Disord; 1999 Oct; 9(6-7):423-33. PubMed ID: 10545049
[TBL] [Abstract][Full Text] [Related]
8. Secondary reduction of alpha7B integrin in laminin alpha2 deficient congenital muscular dystrophy supports an additional transmembrane link in skeletal muscle.
Cohn RD; Mayer U; Saher G; Herrmann R; van der Flier A; Sonnenberg A; Sorokin L; Voit T
J Neurol Sci; 1999 Mar; 163(2):140-52. PubMed ID: 10371075
[TBL] [Abstract][Full Text] [Related]
9. Laminin-α2 Chain-Deficient Congenital Muscular Dystrophy: Pathophysiology and Development of Treatment.
Durbeej M
Curr Top Membr; 2015; 76():31-60. PubMed ID: 26610911
[TBL] [Abstract][Full Text] [Related]
10. Potent pro-inflammatory and pro-fibrotic molecules, osteopontin and galectin-3, are not major disease modulators of laminin α2 chain-deficient muscular dystrophy.
Gawlik KI; Holmberg J; Svensson M; Einerborg M; Oliveira BM; Deierborg T; Durbeej M
Sci Rep; 2017 Mar; 7():44059. PubMed ID: 28281577
[TBL] [Abstract][Full Text] [Related]
11. CD90-positive cells, an additional cell population, produce laminin alpha2 upon transplantation to dy(3k)/dy(3k) mice.
Fukada S; Yamamoto Y; Segawa M; Sakamoto K; Nakajima M; Sato M; Morikawa D; Uezumi A; Miyagoe-Suzuki Y; Takeda S; Tsujikawa K; Yamamoto H
Exp Cell Res; 2008 Jan; 314(1):193-203. PubMed ID: 17963748
[TBL] [Abstract][Full Text] [Related]
12. Natural disease history of the dy2J mouse model of laminin α2 (merosin)-deficient congenital muscular dystrophy.
Pasteuning-Vuhman S; Putker K; Tanganyika-de Winter CL; Boertje-van der Meulen JW; van Vliet L; Overzier M; Plomp JJ; Aartsma-Rus A; van Putten M
PLoS One; 2018; 13(5):e0197388. PubMed ID: 29763467
[TBL] [Abstract][Full Text] [Related]
13. Laminin α1 reduces muscular dystrophy in dy
Gawlik KI; Harandi VM; Cheong RY; Petersén Å; Durbeej M
Matrix Biol; 2018 Sep; 70():36-49. PubMed ID: 29544677
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of the cytotoxic T cell (CT) carbohydrate inhibits muscular dystrophy in the dyW mouse model of congenital muscular dystrophy 1A.
Xu R; Chandrasekharan K; Yoon JH; Camboni M; Martin PT
Am J Pathol; 2007 Jul; 171(1):181-99. PubMed ID: 17591965
[TBL] [Abstract][Full Text] [Related]
15. Merosin and congenital muscular dystrophy.
Miyagoe-Suzuki Y; Nakagawa M; Takeda S
Microsc Res Tech; 2000 Feb 1-15; 48(3-4):181-91. PubMed ID: 10679965
[TBL] [Abstract][Full Text] [Related]
16. Triggering regeneration and tackling apoptosis: a combinatorial approach to treating congenital muscular dystrophy type 1 A.
Yamauchi J; Kumar A; Duarte L; Mehuron T; Girgenrath M
Hum Mol Genet; 2013 Nov; 22(21):4306-17. PubMed ID: 23773998
[TBL] [Abstract][Full Text] [Related]
17. Laminin alpha2 deficiency and muscular dystrophy; genotype-phenotype correlation in mutant mice.
Guo LT; Zhang XU; Kuang W; Xu H; Liu LA; Vilquin JT; Miyagoe-Suzuki Y; Takeda S; Ruegg MA; Wewer UM; Engvall E
Neuromuscul Disord; 2003 Mar; 13(3):207-15. PubMed ID: 12609502
[TBL] [Abstract][Full Text] [Related]
18. Aberrant Caspase Activation in Laminin-α2-Deficient Human Myogenic Cells is Mediated by p53 and Sirtuin Activity.
Yoon S; Beermann ML; Yu B; Shao D; Bachschmid M; Miller JB
J Neuromuscul Dis; 2018; 5(1):59-73. PubMed ID: 29278895
[TBL] [Abstract][Full Text] [Related]
19. Peripheral nerve pathology, including aberrant Schwann cell differentiation, is ameliorated by doxycycline in a laminin-α2-deficient mouse model of congenital muscular dystrophy.
Homma S; Beermann ML; Miller JB
Hum Mol Genet; 2011 Jul; 20(13):2662-72. PubMed ID: 21505075
[TBL] [Abstract][Full Text] [Related]
20. Human laminin-111 and laminin-211 protein therapy prevents muscle disease progression in an immunodeficient mouse model of LAMA2-CMD.
Barraza-Flores P; Hermann HJ; Bates CR; Allen TG; Grunert TT; Burkin DJ
Skelet Muscle; 2020 Jun; 10(1):18. PubMed ID: 32498713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
